Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1978 Oct;6(4):303–309. doi: 10.1111/j.1365-2125.1978.tb00856.x

Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.

P Price, A Debono, J D Parkes, C D Marsden, J Rosenthaler
PMCID: PMC1429466  PMID: 359016

Abstract

1. Plasma bromocriptine levels following separate oral doses of bromocriptine 12.5, 25, 50 and 100 mg have been determined in ten subjects with parkinsonism. 2. There was considerable variation between peak plasma bromocriptine levels in individual subjects after similar doses of bromocriptine. Peak levels occurred 30--210 min after dosage (mean 102 min). Peak clinical response, peak rise in plasma growth hormone level and fall in blood pressure followed shortly after peak bromocriptine levels occurred. 3. The shape of the plasma-time curve for bromocriptine was similar with all dosages. 4. There was no significant relationship between peak plasma bromocriptine levels, peak clinical response, peak increase in growth hormone and peak fall in blood pressure. However, the degree of improvement in the signs of parkinsonism was related to plasma bromocriptine levels was achieved. 5. Metoclopramide 60 mg pretreatment had no consistent effect upon plasma bromocriptine levels, the clinical or hormonal response.

Full text

PDF
303

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brun del Re R., Del Pozo E., De Grandi P., Friesen H., Hinselmann M., Wyss H. Prolactin inhibition and suppression of puerperal lactation by a Br-erocryptine (CB 154). A comparison with estrogen. Obstet Gynecol. 1973 Jun;41(6):884–890. [PubMed] [Google Scholar]
  2. Calne D. B., Teychenne P. F., Claveria L. E., Eastman R., Greenacre J. K., Petrie A. Bromocriptine in Parkinsonism. Br Med J. 1974 Nov 23;4(5942):442–444. doi: 10.1136/bmj.4.5942.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Debono A. G., Donaldson I., Marsden C. D., Parkes J. D. Letter: Bromocriptine in parkinsonism. Lancet. 1975 Nov 15;2(7942):987–988. [PubMed] [Google Scholar]
  4. Del Pozo E., Del Re R. B., Varga L., Friesen H. The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine). J Clin Endocrinol Metab. 1972 Nov;35(5):768–771. doi: 10.1210/jcem-35-5-768. [DOI] [PubMed] [Google Scholar]
  5. Fuxe K., Goldstein M., Hökfelt T., Jonsson G., Lidbrink P. Dopaminergic involvement in hypothalamic function: extrahypothalamic and hypothalamic control. A neuroanatomical analysis. Adv Neurol. 1974;5:405–419. [PubMed] [Google Scholar]
  6. Johnson A. M., Loew D. M., Vigouret J. M. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA. Br J Pharmacol. 1976 Jan;56(1):59–68. doi: 10.1111/j.1476-5381.1976.tb06959.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Johnson A. M., Vigouret J. M., Loew D. M. Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent. Naunyn Schmiedebergs Arch Pharmacol. 1974;282(Suppl):suppl 282–282:R40. [PubMed] [Google Scholar]
  8. Liuzzi A., Chiodini P. G., Botalla L., Cremascoli G., Müller E. E., Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab. 1974 May;38(5):910–912. doi: 10.1210/jcem-38-5-910. [DOI] [PubMed] [Google Scholar]
  9. Martin J. B. Neural regulation of growth hormone secretion. N Engl J Med. 1973 Jun 28;288(26):1384–1393. doi: 10.1056/NEJM197306282882606. [DOI] [PubMed] [Google Scholar]
  10. SCHALCH D. S., PARKER M. L. A SENSITIVE DOUBLE ANTIBODY IMMUNOASSAY FOR HUMAN GROWTH HORMONE IN PLASMA. Nature. 1964 Sep 12;203:1141–1142. doi: 10.1038/2031141a0. [DOI] [PubMed] [Google Scholar]
  11. Shoulson I., Glaubiger G. A., Chase T. N. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975 Dec;25(12):1144–1148. doi: 10.1212/wnl.25.12.1144. [DOI] [PubMed] [Google Scholar]
  12. Snider S. R., Hutt C., Stein B., Prasad A. L., Fahn S. Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover. J Pharm Pharmacol. 1976 Jul;28(7):563–566. doi: 10.1111/j.2042-7158.1976.tb02796.x. [DOI] [PubMed] [Google Scholar]
  13. Verde G., Oppizzi G., Colussi G., Cremascoli G., Botalla L., Müller E. E., Silvestrini F., Chiodini P. G., Liuzzi A. Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in agromegalic patients. Clin Endocrinol (Oxf) 1976 Jul;5(4):419–423. doi: 10.1111/j.1365-2265.1976.tb01971.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES